CALCULATE YOUR SIP RETURNS

Syncom Formulations (India) Share Price Live

SYNCOMF

Small Cap | Pharmaceuticals

15.85

-0.15(0.94%)

Live Syncom Formulations (India) Share Price Chart

Syncom Formulations (India) Performance

Days Range

Previous Close₹16.00
Open₹16
Volume7,76,970
Day's Range₹15.80 - ₹16.06
52W Range₹14.10 - ₹23.87
Market Cap₹1,503.06 Cr

Syncom Formulations (India) Fundamentals

ROCE(TTM)22.00
P/E Ratio (TTM)23.87
P/B Ratio3.97
Industry P/E33.19
Debt to Equity0
ROE16.66
EPS (TTM)0.67
Dividend Yield0
Book Value4.03
Face Value1
ROCE(TTM)22.00
P/E Ratio (TTM)23.87
P/B Ratio3.97
Industry P/E33.19
Debt to Equity0
ROE16.66
EPS (TTM)0.67
Dividend Yield0
Book Value4.03
Face Value1

Syncom Formulations (India) Financials

Dec 2024Mar 2025Jun 2025Sep 2025
Net Sales127.53148.88116.90121.72
Expenses114.11132.41102.43104.67
Profit before tax17.2623.3020.2922.04
Operating Profit13.0017.6915.7516.60
Net Profit13.0017.6915.7516.60
ESP in Rs0.140.160.210.18

Syncom Formulations (India) Shareholding Pattern

Held bySep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Promoters50.57%50.57%50.57%50.57%50.57%
Flls0.1%0.13%0.11%0.41%0.1%
Dlls0%0%0%0%0%
Public49.33%49.3%49.32%49.02%49.33%

About Syncom Formulations (India)

Incorporated as a private limited Company in 1988, Syncom Formulations (India) Limited was converted into a public limited Company in June, 1992. The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency. Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards. Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations. Commercial production commenced in Apr.'89. Promoters are Kedarmal Bankda, Vijay Kumar Bankda and Ajay Kumar Bankda. In addition to pharmaceutical formulations in the form of tablets, capsules, liquids and dry powders, the company also manufactures injectibles and ear/eye drops on a loan licence basis. In 1994, the company undertook an expansion programme of setting up a new plant for manufacturing pharmaceutical formulations at Pithampur, Madhya Pradesh. The project which was financed through a public issue made in Jan.'94 was completed in 1995. During the year 1997-98, the Company has further diversified into Ethical Operations by introducing the range of prescription formulations. During the year 1998-99 there has been huge expansion of installed capacity and production base. Further the company plans introduction of products in the generic, OTC and Ethical Divisions. The export earnings have also registered a growth of more than 100%. During the year 1999-2000, the company and its associates have received export orders worth Rs.700.00 lacs against advance payment and hence better turnover is expected during the year. The company presently exports goods to Guine, Ghana, Kenya, Tanzania, Nigeria in Africa, Azberjan, Nepal and Srilanka in Asia. The company has been approved as a supplier to Central ESI Hospitals and registration of defence services is in its final stages, as a result of which will generate substantial sales volume. Keeping in view the shifting consumer preferenes for the use of herbal products, the company is aggressively manufacturing and marketing its herbal products like Edicare, Attom Megacaps, Ecziguard and Yas antacid salt. The modernisation of injectable section by putting Tunnel System and other modern equipments and expansion of tablet department by putting high speed mega press machines was completed in 2002. The Company carried out an expansion program of the installed capacities of its manufacturing unit at Pithampur, Dist. Dhar to increase the capacity of tablet section by 35% and also doubling of the capacity of capsule section. Capacity of packing section was increased in line with the increase in capacity of the said formulation sections. The expansion cum modernization program was implemented at a total cost of Rs. 1.34 crore out of which the major expenditure was incurred in 2002-03. The expanded capacities were made available for production from May, 2003. In 2007, the Company launched a new division 'Cratus Life Care' to expand its operations. The expansion cum modernization project at Pithampur unit was completed with the total investment costing Rs 15.17 Crore during the year 2007-08. The Company raised long term financial resources by way of preference issuance of 3,10,000 equity shares of Rs.10 each at a premium of Rs.36 per share on 29 March, 2008 to the promoters of the Company and the said Equity got listed with the BSE in 2008. In 2023-24, Company has expanded the business by increasing the overall production capacity of Injectable capacity from 200 Lakhs to 300 Lakhs per annum.

Parent Organisation
Indian Private
Managing Director
ANKIT KEDARMAL BANKDA
Founded
1988
NSE Symbol
SYNCOMF

Syncom Formulations India Share Price History

Syncom Formulations India Share Price History

ParticularsDetails
5-Year % change in Syncom Formulations India share price102.84%
5-Year Highest in Syncom Formulations India share price₹ 27.9
5-Year Lowest in Syncom Formulations India share price₹ 4.6
1-Year % change in Syncom Formulations India share price23.53%
1-Year Highest in Syncom Formulations India share price₹ 27.9
1-Year Lowest in Syncom Formulations India share price₹ 10.95

Top Mutual Funds Invested in Syncom Formulations India Share

Top Mutual Funds Invested in Syncom Formulations India Share

Peer Comparison

Peer Comparison

StocksLTP (₹)Market Cap (cr)52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd1,786.5
9.10 (0.51%)
₹4,26,565.771,548.0 - 1,910.0View Stocks
Divis Laboratories Ltd6,413.5
-49.00 (-0.76%)
₹1,71,593.584,955.0 - 7,071.5View Stocks
Torrent Pharmaceuticals Ltd3,713.5
-7.90 (-0.21%)
₹1,25,819.902,886.45 - 3,882.2View Stocks
Cipla Ltd1,521.7
-7.50 (-0.49%)
₹1,23,504.181,335.0 - 1,673.0View Stocks
Dr Reddys Laboratories Ltd1,247.1
-1.50 (-0.12%)
₹1,04,131.511,020.0 - 1,405.9View Stocks
Zydus Lifesciences Ltd925.9
-2.10 (-0.23%)
₹93,338.26795.0 - 1,059.05View Stocks

Syncom Formulations India Ltd FAQs

Syncom Formulations India Ltd (SYNCOMF) share price as of November 21, 2025, on NSE is Rs 15.85 (NSE) and Rs 15.85 (BSE) on BSE.
Yes, You can buy Syncom Formulations India Ltd (SYNCOMF) shares by opening a Demat account with Angel One.
Syncom Formulations India Ltd (SYNCOMF) share can be bought through the following modes:
1. Direct investment: You can buy Syncom Formulations India Ltd (SYNCOMF) shares by opening a Demat account with Angel One.
2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Syncom Formulations India Ltd (SYNCOMF) shares.
Open Free Demat Account!
Join our 3 Cr+ happy customers